Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case report

被引：4

作者：

Kattan, Joseph ^{[1
]}

Kattan, Clarisse ^{[1
]}

Farhat, Fadi ^{[2
]}

Assi, Tarek ^{[2
,3
]}

机构：

[1] St Joseph Univ, Hotel Dieu France Univ Hosp, Hematol Oncol Dept, Fac Med, Beirut, Lebanon

[2] Hammoud Hosp UMC, Hematol Oncol Dept, Saida, Lebanon

[3] St Joseph Univ, Hematol Oncol Dept, Fac Med, Beirut, Lebanon

来源：

ANTI-CANCER DRUGS | 2019年 / 30卷 / 10期

关键词：

binimetinib; BRAF; encorafenib; immune checkpoint; MEK; melanoma; resistance; METASTATIC MELANOMA; MUTANT MELANOMA; OPEN-LABEL; NIVOLUMAB; COMBINATION; DABRAFENIB; TRAMETINIB; IPILIMUMAB; EFFICACY; STANDARD;

D O I：

10.1097/CAD.0000000000000827

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The advent of BRAF and MEK inhibitors changed the landscape of the management of BRAF mutated melanoma patients. In this article, we report the case of a 51-year-old man with BRAF mutated locally advanced cutaneous melanoma of the head who demonstrated a limited response to initial anti-BRAF monotherapy followed by extensive surgery. Anti-PD1 therapy failed to reverse the disease progression. However, subsequent double inhibition of the BRAF and MEK pathways induced a fast and remarkable tumour response.

引用

页码：1052 / 1054

页数：3

共 50 条

[21] BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma
Paola Queirolo
Francesco Spagnolo
Cancer and Metastasis Reviews, 2017, 36 : 35 - 42
[22] Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
Welsh, Sarah J.
Corrie, Pippa G.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2015, 7 (02) : 122 - 136
[23] The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era
Vito Vanella
Lucia Festino
Claudia Trojaniello
Maria Grazia Vitale
Antonio Sorrentino
Miriam Paone
Paolo A. Ascierto
Current Oncology Reports, 2019, 21
[24] "Re-re-treatment?" Third and fourth courses of BRAF/MEK inhibition in advanced melanoma
O'Brien, Michael T.
Iwamoto, Sage
Haq, Rizwan
Johnson, Douglas B.
EUROPEAN JOURNAL OF CANCER, 2025, 220
[25] Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy
Kuske, Marvin
Westphal, Dana
Wehner, Rebekka
Schmitz, Marc
Beissert, Stefan
Praetorius, Christian
Meier, Friedegund
PHARMACOLOGICAL RESEARCH, 2018, 136 : 151 - 159
[26] Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma
Carlino, Matteo S.
Todd, Jason R.
Gowrishankar, Kavitha
Mijatov, Branka
Pupo, Gulietta M.
Fung, Carina
Snoyman, Stephanie
Hersey, Peter
Long, Georgina V.
Kefford, Richard F.
Rizos, Helen
MOLECULAR ONCOLOGY, 2014, 8 (03) : 544 - 554
[27] Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab
Moser, Justin C.
Chen, Danli
Hu-Lieskovan, Siwen
Grossmann, Kenneth F.
Patel, Shiven
Colonna, Sarah, V
Ying, Jian
Hyngstrom, John R.
CANCER MEDICINE, 2019, 8 (18): : 7637 - 7643
[28] MEK inhibitors for the treatment of immunotherapy-resistant, AGK-BRAF fusion advanced acral melanoma: a case report and literature review
Zhang, Yanling
Zhang, Xifeng
Shao, Weikang
Gao, Ji
Xiang, Mei
Wang, Yan
Liu, Mengmeng
Zhang, Weizhen
Liang, Xianbin
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2025, 151 (04)
[29] Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials
Liu, Mengdong
Yang, Xuekang
Liu, Jiaqi
Zhao, Bin
Cai, Weixia
Li, Yan
Hu, Dahai
ONCOTARGET, 2017, 8 (19) : 32258 - 32269
[30] The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma
Dimitriou, Florentia
Urner-Bloch, Ursula
Eggenschwiler, Corinne
Mitsakakis, Nicholas
Mangana, Joanna
Dummer, Reinhard
Urner, Martin
EUROPEAN JOURNAL OF CANCER, 2021, 144 : 215 - 223

← 1 2 3 4 5 →